Absci Shares Jump on Renewed Optimism for Hair-Loss Therapies
Absci Corp's stock climbed sharply in early trading after analysts pointed to encouraging mid-to-late stage data from a rival and a sizable estimated market for hair-loss treatments. KeyBanc reiterated a $9 target on Absci and suggested the company's experimental therapy could act as a complement to existing options rather than a direct substitute.